By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
An assay is a method for analytical measurement that generates a detectable signal for calculating the amount of a biological process. The consistency and reliability of the signal in the absence of a test substance serve as a measure of an assay’s quality.
Biochemical tests and cell-based assays are the two main types of assays used in the drug development process. The first kind of assay that is frequently employed is a biochemical assay. The target protein can be evaluated and examined using biochemical assays, and molecules with the required activity at the target can be found.
Bioassays are an useful source of knowledge about the effectiveness of biological products. This is crucial for assessing the consistency and stability of batches. At every stage of the development of biological products, from initial research to final quality control of finished goods, bioassay data are essential.
The creation of test methods (assays) for assessing the effects of chemical compounds on relevant cellular, molecular, or biochemical processes is known as development and toxicity testing. Ideas for tests are submitted by researchers in the field of biomedicine.
Global drug discovery support assays market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Lilly releases an open innovation drug discovery platform to aid in the search for potential new medications in areas with high medical need. the launch of a new open innovation platform intended to assist in developing the company’s pipeline of the future and, from a charitable standpoint, uncover compounds that may have use in treating multi-drug resistant tuberculosis (MDR-TB). Known as Open Innovation Drug Discovery, the new platform.
It expands on Lilly’s Phenotypic Drug Discovery Initiative (PD2), which was established in 2009 and has been successful in facilitating research on molecules all over the world that may one day be turned into medicines.
An additional new element that utilises the Lilly TB Drug Discovery Initiative to screen molecules for their potential in the fight against MDR-TB, a type of tuberculosis (TB) that is resistant to at least two first-line TB medications.
Lilly has long contributed to international initiatives aimed at halting the MDR-TB and TB epidemics, which disproportionately afflict marginalised groups. There is an urgent need for new treatments due to the MDR-recent TB’s emergence.
